TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9744373

Group type: EXPERIMENTAL
Intervention: Brinzolamide 1.0% twice daily
Number of subjects: 572

Group type: EXPERIMENTAL
Intervention: Brinzolamide 1.0% three times daily
Number of subjects: 572

Group type: COMPARATOR
Intervention: Dorzolamide 2.0% three times daily
Number of subjects: 572

Group type: COMPARATOR
Intervention: Timolol 0.5% twice daily
Number of subjects: 572

Group type: EXPERIMENTAL
Intervention: Brinzolamide 1.0% (twice daily)
Number of subjects: 572

Group type: EXPERIMENTAL
Intervention: Brinzolamide 1.0% (three times daily)
Number of subjects: 572

Group type: COMPARATOR
Intervention: Dorzolamide
Number of subjects: 572
Study: 7544184

Group type: EXPERIMENTAL
Intervention: Immunotherapy
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Pollen season
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group (before immunotherapy)
Number of subjects: 17
Study: 2754576

Group type: EXPERIMENTAL
Intervention: Multifamily plus parent simulation of diabetes (MF + S)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Multifamily (MF)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Smaller family groups (part of MF or MF + S)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 32
Study: 869668

Group type: EXPERIMENTAL
Intervention: Imipramine hydrochloride (various doses)
Number of subjects: 0
Study: 29128317

Group type: EXPERIMENTAL
Intervention: Lactobacillus GG (6×10^9 CFU/day)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study: 27982269

Group type: EXPERIMENTAL
Intervention: ReHOT clinical trial participation
Number of subjects: 109
Study: 26302034

Group type: EXPERIMENTAL
Intervention: Low-fat yoghurt supplemented with 80 mg d(‐1) of rooster comb extract (RCE)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo group (same yoghurt without RCE)
Number of subjects: 40
Study: 24041934

Group type: EXPERIMENTAL
Intervention: Two-stage nursing assessment and intervention after discharge and at follow-up
Number of subjects: 271

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 271
Study: 20473703

Group type: EXPERIMENTAL
Intervention: EORTC QLQ-C30 questionnaire
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mapping from QLQ-C30 to EQ-5D
Number of subjects: 0
Study: 18262688

Group type: EXPERIMENTAL
Intervention: Modified cornstarch pudding (25g carbohydrate in 150g water)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Modified cornstarch stew (25g carbohydrate in 300g water)
Number of subjects: 8

Group type: COMPARATOR
Intervention: White bread (control)
Number of subjects: 8
Study: 16647404

Group type: EXPERIMENTAL
Intervention: Pamidronate therapy
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control (patients who had not received pamidronate)
Number of subjects: 59
Study: 14659383

Group type: EXPERIMENTAL
Intervention: Oncology social workers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oncology physicians
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oncology nurses
Number of subjects: 0
Study: 10824468

Group type: EXPERIMENTAL
Intervention: Epsilon aminocaproic acid (100 mg/kg body wt) intravenously slowly soon after anaesthetic induction, followed by 100 mg/kg in the cardiopulmonary bypass pump and 100 mg/kg after weaning from bypass over a period of 3 h
Number of subjects: 170

Group type: COMPARATOR
Intervention: Normal saline as placebo (control group)
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Epsilon aminocaproic acid
Number of subjects: 170
Study: 9035702

Group type: EXPERIMENTAL
Intervention: Tazarotene
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Once-daily treatment of Tazarotene
Number of subjects: 0
Study: 1627203

Group type: EXPERIMENTAL
Intervention: Sertaconazole 1% cream applied twice a day for 4 weeks
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Sertaconazole 2% cream applied twice a day for 4 weeks
Number of subjects: 21
Study: 6148959

Group type: EXPERIMENTAL
Intervention: Bisoprolol 20 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Bisoprolol 40 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Metoprolol 200 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Propranolol 80 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 30882595

Group type: COMPARATOR
Intervention: Consumption of at least five servings per week of fish
Number of subjects: 12279

Group type: COMPARATOR
Intervention: Highest quintile of omega-3 fatty acid intake
Number of subjects: 12279
Study: 29105259

Group type: EXPERIMENTAL
Intervention: Classification Tree Analysis (CTA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Structural Equation Models (SEMs)
Number of subjects: 0
Study: 27311311

Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine (2% CHX-a)
Number of subjects: 3682

Group type: EXPERIMENTAL
Intervention: <1% chlorhexidine (<1% CHX-a)
Number of subjects: 3682

Group type: EXPERIMENTAL
Intervention: 10% povidone-iodine (PVI)
Number of subjects: 3682

Group type: COMPARATOR
Intervention: Other antiseptics
Number of subjects: 3682
Study: 24925722

Group type: EXPERIMENTAL
Intervention: Renin-angiotensin system inhibitors (mostly but not entirely)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 159
Study: 22465578

Group type: EXPERIMENTAL
Intervention: Mirasol‐inactivated fresh frozen plasma (FFP)
Number of subjects: 60

Group type: COMPARATOR
Intervention: noninactivated fresh frozen plasma (FFP)
Number of subjects: 60
Study: 20718287

Group type: EXPERIMENTAL
Intervention: Feelings of betrayal by the UNHCR
Number of subjects: 22
Study: 18039351

Group type: EXPERIMENTAL
Intervention: BAY 79‐4980 (13 or 22 mg kg(‐1) pegylated liposomes)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Standard rFVIII‐FS (35 IU kg(‐1))
Number of subjects: 26
Study: 16200601

Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg subcutaneously every other week for 24 weeks
Number of subjects: 313

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 313
Study: 14612278

Group type: EXPERIMENTAL
Intervention: Intermittent Pringle manoeuvre
Number of subjects: 131

Group type: COMPARATOR
Intervention: Control (without Pringle manoeuvre)
Number of subjects: 131
Study: 10088982

Group type: EXPERIMENTAL
Intervention: Relaxation
Number of subjects: 225

Group type: COMPARATOR
Intervention: Frustration
Number of subjects: 225

Group type: COMPARATOR
Intervention: Harassment
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Low educational level
Number of subjects: 225
Study: 7555033

Group type: EXPERIMENTAL
Intervention: 1 capsule twice daily (A)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 2 capsules in the morning and 1 in the evening (B)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 2 capsules twice daily (C)
Number of subjects: 21
Study: 2258450

Group type: EXPERIMENTAL
Intervention: Amoxapine 400 mg
Number of subjects: 92

Group type: COMPARATOR
Intervention: Amitriptyline 300 mg
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Amoxapine and Amitriptyline
Number of subjects: 92
Study: 7008475

Group type: EXPERIMENTAL
Intervention: Low dose heparin (LDH)
Number of subjects: 2
Study: 31900193

Group type: EXPERIMENTAL
Intervention: Lottery prizes based on timely clinic visits and demonstration of viral suppression (T1, n=110)
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Lottery prizes conditional on high adherence measured by a medication event management system (MEMS) cap (T2, n=110)
Number of subjects: 330

Group type: COMPARATOR
Intervention: Usual standard of care (Control, n=110)
Number of subjects: 330
Study: 30539411

Group type: EXPERIMENTAL
Intervention: IMR-cCTA (80 kV; automated-mAs; 60 mL of CM, 350 mgL/mL)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: IMR-cCTA
Number of subjects: 98

Group type: COMPARATOR
Intervention: iDose-cCTA
Number of subjects: 98
Study: 27190943

Group type: EXPERIMENTAL
Intervention: ACP-CPP chewing gum
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Natural chewable products (Tulsi, sesame seeds, fennel seeds, coconut)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Coconut group
Number of subjects: 10

Group type: COMPARATOR
Intervention: Fennel group
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Recaldent (ACP-CPP)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Sesame group
Number of subjects: 10
Study: 24350624

Group type: EXPERIMENTAL
Intervention: Surgical treatment with totally extraperitoneal endoscopic mesh placement
Number of subjects: 30

Group type: COMPARATOR
Intervention: Normal MRI group (without BME)
Number of subjects: 30
Study: 24471210

Group type: EXPERIMENTAL
Intervention: Increased intake of fatty fish
Number of subjects: 105
Study: 21212768

Group type: EXPERIMENTAL
Intervention: CAL-DEP (calorie deprived state, <10% of estimated energy requirements)
Number of subjects: 13

Group type: COMPARATOR
Intervention: FED (fully fed state)
Number of subjects: 13
Study: 19920416

Group type: EXPERIMENTAL
Intervention: Mepivacaine 400 mg diluted in 20 mL
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Mepivacaine 400 mg diluted in 30 mL
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Mepivacaine 400 mg diluted in 40 mL
Number of subjects: 165
Study: 17075243

Group type: EXPERIMENTAL
Intervention: Anorexia nervosa patients before weight restoration
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Anorexia nervosa patients after weight restoration
Number of subjects: 26

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 26
Study: 14756642

Group type: EXPERIMENTAL
Intervention: Long‐pulsed 1320‐nm Nd:YAG laser
Number of subjects: 20

Group type: COMPARATOR
Intervention: Long‐pulsed 1450‐nm diode laser
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Patient satisfaction scores
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: In vivo microtopography measurements
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Side effects of treatment
Number of subjects: 20
Study: 11708314

Group type: EXPERIMENTAL
Intervention: Protein supplement (10 g protein, 7 g carbohydrate, 3.3 g fat, and one-third of RDA of vitamins and minerals) ingested immediately after exercise.
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group (C) did not ingest the protein supplement.
Number of subjects: 17
Study: 9514139

Group type: EXPERIMENTAL
Intervention: 100 mg/kg of AA, daily for the first week of life
Number of subjects: 51

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 51
Study: 8088970

Group type: EXPERIMENTAL
Intervention: ATP-MgCl2
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 3406600

Group type: EXPERIMENTAL
Intervention: Drugs or relaxation therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 31129371

Group type: EXPERIMENTAL
Intervention: Intensive Telephone Counseling (ITC; eight proactive sessions/eight weeks of nicotine patches, plus discussion of the LCS results)
Number of subjects: 1330

Group type: COMPARATOR
Intervention: Usual Care (UC; three proactive telephone counseling sessions/two weeks of nicotine patches)
Number of subjects: 1330

Group type: EXPERIMENTAL
Intervention: Both interventions (ITC and UC)
Number of subjects: 1330

Group type: EXPERIMENTAL
Intervention: Six SCALE trials (including LSTH)
Number of subjects: 1330
Study: 30039526

Group type: EXPERIMENTAL
Intervention: Vitamin C supplementation in group B (Bio‐Oss Collagen)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Vitamin C supplementation in groups A (guided bone regeneration) and C (chronic periodontitis)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Vitamin C supplementation in group D (no bone grafting or periodontal disease)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Vitamin C supplementation for pain relief
Number of subjects: 128
Study: 26780271

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) adjunct to scaling and root planing (SRP)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional non-surgical periodontal therapy (NSPT)
Number of subjects: 20
Study: 24996197

Group type: EXPERIMENTAL
Intervention: Brivanib 800 mg orally once-daily
Number of subjects: 502

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 502
Study: 22406155

Group type: EXPERIMENTAL
Intervention: Anti-TB drug treatment
Number of subjects: 40
Study: 19783386

Group type: EXPERIMENTAL
Intervention: Modafinil (200, 400, or 600 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 17645384

Group type: EXPERIMENTAL
Intervention: Music therapy plus cardiac rehabilitation
Number of subjects: 68

Group type: COMPARATOR
Intervention: Cardiac rehabilitation only
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Music therapy
Number of subjects: 68
Study: 15846252

Group type: EXPERIMENTAL
Intervention: Screening for CAD (exercise electrocardiogram test and dipyridamole stress echocardiography)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Control (no screening)
Number of subjects: 141
Study: 10961514

Group type: COMPARATOR
Intervention: Normal (22 degrees C/30% RH)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Wet (30 degrees C/85% RH)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Hot (40 degrees C/40% RH)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Post exercise
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Weight measurements
Number of subjects: 8
Study: 9051540

Group type: COMPARATOR
Intervention: IV ondansetron 4 mg and saline
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: IV ondansetron 4 mg followed by IV dexamethasone 20 mg
Number of subjects: 80
Study: 8358475

Group type: EXPERIMENTAL
Intervention: Chest tube stripping
Number of subjects: 16

Group type: COMPARATOR
Intervention: No chest tube stripping
Number of subjects: 16
Study: 3002987

Group type: EXPERIMENTAL
Intervention: Group B polysaccharide and OMV vaccine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo vaccine
Number of subjects: 30
Study: 3403868

Group type: EXPERIMENTAL
Intervention: Theolan Suspension (administered every 12 hours)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Aminophylline solution (administered every 8 hours)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Theolan Suspension
Number of subjects: 27

Group type: COMPARATOR
Intervention: Aminophylline solution
Number of subjects: 27
Study: 31915170

Group type: EXPERIMENTAL
Intervention: Personalised intervention including interactive responses and medication and follow-up reminders, in addition to usual care and general educational messages.
Number of subjects: 760

Group type: COMPARATOR
Intervention: Usual care and general educational messages on medical knowledge.
Number of subjects: 760
Study: 30849947

Group type: EXPERIMENTAL
Intervention: Healthy walking (4 km at low-moderate intensity)
Number of subjects: 89
Study: 28011243

Group type: EXPERIMENTAL
Intervention: Drug-Eluting Balloon (DEB)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Paclitaxel-Eluting Stent (PES)
Number of subjects: 182
Study: 26790201

Group type: EXPERIMENTAL
Intervention: Interactive dynamic scalp acupuncture therapy
Number of subjects: 70

Group type: COMPARATOR
Intervention: Traditional scalp acupuncture therapy
Number of subjects: 70
Study: 23143672

Group type: EXPERIMENTAL
Intervention: Individualized mailed CVD risk messages
Number of subjects: 435
Study: 21569309

Group type: EXPERIMENTAL
Intervention: Sertraline (titration up to the minimum vs maximum of the recommended dose range)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sertraline (staying on sertraline)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sertraline (augmentation with mirtazapine)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mirtazapine (switching from sertraline to mirtazapine)
Number of subjects: 0
Study: 19594842

Group type: EXPERIMENTAL
Intervention: Real TMS (10 Hz left prefrontal repetitive TMS, 20-minute sessions)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Sham TMS
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Real TMS
Number of subjects: 4
Study: 16491578

Group type: EXPERIMENTAL
Intervention: Unpredictable accelerations triggered by the experimenter
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Self-triggered acceleration
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Predictable accelerations triggered by subjects pressing a button
Number of subjects: 19
Study: 15605345

Group type: EXPERIMENTAL
Intervention: Electric stimulation facilitation program
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard physical therapy (PT) care
Number of subjects: 20
Study: 11370405

Group type: EXPERIMENTAL
Intervention: Drug information from the pharmaceutical industry
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Producer independent information
Number of subjects: 0
Study: 9232299

Group type: EXPERIMENTAL
Intervention: Monitoring orbicularis oculi (OO)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Monitoring adductor pollicis (AP)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both groups (OO and AP)
Number of subjects: 30
Study: 7683480

Group type: EXPERIMENTAL
Intervention: Clodronate (C) with estramustine phosphate (E)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Estramustine phosphate (E)
Number of subjects: 99
Study: 2961688

Group type: EXPERIMENTAL
Intervention: Synthetic atrial natriuretic factor (ANF) at 0.20 microgram/kg/min
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Synthetic atrial natriuretic factor (ANF) at 0.45 microgram/kg/min
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Synthetic atrial natriuretic factor (ANF) at 0.03 microgram/kg/min
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Synthetic atrial natriuretic factor (ANF)
Number of subjects: 8

Group type: COMPARATOR
Intervention: High sodium diet (200 mEq/day)
Number of subjects: 8
Study: 31890625

Group type: EXPERIMENTAL
Intervention: Uni Virtual Clinic (UVC) intervention
Number of subjects: 200

Group type: COMPARATOR
Intervention: Waitlist control condition
Number of subjects: 200
Study: 26181001

Group type: EXPERIMENTAL
Intervention: Self-training (including a manikin and access to a web-based video on PBLS)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Instructor-led course (2-hour duration)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Self-training
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Self-training and Instructor-led training
Number of subjects: 58
Study: 24848990

Group type: EXPERIMENTAL
Intervention: Paracetamol 1000 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ibuprofen sodium 400 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ibuprofen-poloxamer 400 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 0
Study: 24128134

Group type: EXPERIMENTAL
Intervention: Sirolimus (initiated at 2 mg/d, adjusted to 6 to 8 ng/mL)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Sirolimus
Number of subjects: 25

Group type: COMPARATOR
Intervention: Cyclosporine (control group)
Number of subjects: 25
Study: 21403463

Group type: EXPERIMENTAL
Intervention: DTwP‐HBV+Hib vaccine (SIIL)
Number of subjects: 100

Group type: COMPARATOR
Intervention: TritanrixHB+Hiberix vaccine (GSK)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Booster dose for both SIIL and GSK groups
Number of subjects: 100
Study: 18715826

Group type: EXPERIMENTAL
Intervention: Access arm with diagnostic information from the implantable device and fluid alert algorithm.
Number of subjects: 2400

Group type: COMPARATOR
Intervention: Control arm without access to diagnostic information.
Number of subjects: 2400

Group type: EXPERIMENTAL
Intervention: Access arm with diagnostic information from the implantable device.
Number of subjects: 2400
Study: 16574735

Group type: EXPERIMENTAL
Intervention: Modified Oxford PTA Scale (MOPTAS)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Westmead PTA Scale (WPTAS)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Galveston Orientation and Amnesia Test (GOAT)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Cognitive and behavioral measurements at time 1 and time 2
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Cognitive measurements between time 2 and time 3
Number of subjects: 82
Study: 12704972

Group type: EXPERIMENTAL
Intervention: Rehabilitation (R)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 133
Study: 10879992

Group type: EXPERIMENTAL
Intervention: Cetirizine treatment for 6 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cetirizine treatment for 1 week
Number of subjects: 0
Study: 9095569

Group type: EXPERIMENTAL
Intervention: Mexiletine
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Flecainide
Number of subjects: 21
Study: 8249653

Group type: EXPERIMENTAL
Intervention: Mianserin
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 3535490

Group type: EXPERIMENTAL
Intervention: Oral milrinone therapy (10 +/- 1 weeks)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Intravenous milrinone after withdrawal of oral drug for 24 hours
Number of subjects: 9

Group type: COMPARATOR
Intervention: Withdrawal of oral milrinone
Number of subjects: 9
Study: 31338575

Group type: EXPERIMENTAL
Intervention: Antiadhesive agent
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (no antiadhesive agent)
Number of subjects: 80
Study: 29119530

Group type: EXPERIMENTAL
Intervention: Liver resection
Number of subjects: 484

Group type: EXPERIMENTAL
Intervention: Risk-scoring model based on AFP, tumour number, and Vp4 PVTT
Number of subjects: 484

Group type: EXPERIMENTAL
Intervention: Prognostic nomogram
Number of subjects: 484
Study: 26876503

Group type: EXPERIMENTAL
Intervention: Fluency covered stent
Number of subjects: 258
Study: 24641978

Group type: EXPERIMENTAL
Intervention: Acute heroin administration
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 22243563

Group type: EXPERIMENTAL
Intervention: Naltrexone (25 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: THC (0.025 mg/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 20411690

Group type: EXPERIMENTAL
Intervention: Empiric auto-titrating CPAP
Number of subjects: 109

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 109

Group type: COMPARATOR
Intervention: Fixed CPAP after polysomnography (control group)
Number of subjects: 109
Study: 17667678

Group type: EXPERIMENTAL
Intervention: Transpalatal arch fixed retention
Number of subjects: 30

Group type: COMPARATOR
Intervention: No retention
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Comparison between groups
Number of subjects: 30